SCHEMBL9280109

SCHEMBL9280109

CCOC(=O)C(C#N)=C(Cc1ccccc1)OCC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.47
MEN1 O00255 4/20 0.47
MAPT P10636 7/20 0.44
ALDH1A1 P00352 5/20 0.44
PKM P14618 2/20 0.44
MAPK1 P28482 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
KDM4E B2RXH2 1/20 0.44
HSD17B10 Q99714 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.42
LMNA P02545 2/20 0.42
RAB9A P51151 2/20 0.42
USP2 O75604 1/20 0.42
CRHBP P24387 1/20 0.42
CRHR2 Q13324 1/20 0.42
GAA P10253 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
DHODH Q02127 1/20 0.41
TP53 P04637 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9760357 0.87 KMT2A (0.48) KMT2AMEN1MAPTALDH1A1PKM
SCHEMBL25883387 0.87 KMT2A (0.48) KMT2AMEN1MAPTALDH1A1PKM
SCHEMBL9279794 0.87 KMT2A (0.48) KMT2AMEN1MAPTALDH1A1PKM
SCHEMBL10271717 0.85 KMT2A (0.47) KMT2AMEN1MAPTALDH1A1PKM
SCHEMBL9276683 0.84 KMT2A (0.49) KMT2AMEN1MAPTALDH1A1PKM
SCHEMBL11256576 0.84 KMT2A (0.46) KMT2AMEN1MAPTALDH1A1PKM
SCHEMBL25883431 0.84 KMT2A (0.49) KMT2AMEN1MAPTALDH1A1PKM
SCHEMBL11256579 0.84 KMT2A (0.46) KMT2AMEN1MAPTALDH1A1PKM
SCHEMBL9276687 0.84 KMT2A (0.49) KMT2AMEN1MAPTALDH1A1PKM
SCHEMBL15170431 0.80 MEN1 (0.49) KMT2AMEN1MAPTALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8933095-B2 KAT II inhibitors PFIZER INC. (US) 2015-01-13 US disclosed
EP-2646443-B1 KAT II INHIBITORS PFIZER (US) 2014-09-24 EP disclosed
US-20140057938-A1 KAT ll INHIBITORS PFIZER INC. (US) 2014-02-27 US disclosed
US-8598200-B2 KAT II inhibitors PFIZER INC. (US) 2013-12-03 US disclosed
EP-2646443-A1 KAT II INHIBITORS Pfizer Inc (US) 2013-10-09 EP disclosed
US-20120302599-A1 KAT ll INHIBITORS PFIZER INC 2012-11-29 US disclosed
WO-2012073143-A1 KAT II INHIBITORS PFIZER INC. (US) 2012-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140057938-A1 KAT ll INHIBITORS KAT2A, KAT7, KAT5 KMT2A 215/4885MEN1 4642/4885MAPT 126/4885
US-20120302599-A1 KAT ll INHIBITORS KAT2A, KAT7, KAT5 KMT2A 215/4885MEN1 4642/4885MAPT 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.